Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237426 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
A Phase 2 study, sponsored by Transcend Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT06237426 is a Phase 2 study that has completed, run by Transcend Therapeutics. The registered enrollment target is 44 participants.
The verdict
NCT06237426, a Phase 2 study, has completed, sponsored by Transcend Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD symptoms will be assessed at each observational visit and if criteria for Relapse has been met, participants may be eligible to receive a course of TSND-201 treatment.
Interventions
- DRUG Methylone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2024-03-06 |
| Est. Completion | 2025-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06237426
The ClinicalTrials.gov registry entry for NCT06237426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Transcend Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methylone is the first listed.
NCT06237426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06237426 about?
NCT06237426 is a clinical study titled "An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD". This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD s...
What is the current status of trial NCT06237426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2024-03-06. Estimated completion is 2025-10-06.
What interventions are being tested in trial NCT06237426?
The interventions under investigation include: Methylone (DRUG).
Who is sponsoring clinical trial NCT06237426?
This trial is sponsored by Transcend Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.